"Intravitreal Injections" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.
| Descriptor ID |
D058449
|
| MeSH Number(s) |
E02.319.267.530.475.500
|
| Concept/Terms |
Intravitreal Injections- Intravitreal Injections
- Injection, Intravitreal
- Injections, Intravitreal
- Intravitreal Injection
|
Below are MeSH descriptors whose meaning is more general than "Intravitreal Injections".
Below are MeSH descriptors whose meaning is more specific than "Intravitreal Injections".
This graph shows the total number of publications written about "Intravitreal Injections" by people in this website by year, and whether "Intravitreal Injections" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 5 | 5 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 6 | 6 |
| 2017 | 0 | 8 | 8 |
| 2018 | 0 | 4 | 4 |
| 2019 | 1 | 4 | 5 |
| 2020 | 0 | 4 | 4 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 5 | 6 |
| 2024 | 1 | 7 | 8 |
| 2025 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Intravitreal Injections" by people in Profiles.
-
Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmic Surg Lasers Imaging Retina. 2025 Aug; 56(8):468-477.
-
Early Outcomes After Initiation of Faricimab in Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2025 Aug; 56(8):478-486.
-
Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. JAMA Ophthalmol. 2025 04 01; 143(4):326-335.
-
Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Am J Ophthalmol. 2025 Jul; 275:14-26.
-
Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study. Eye (Lond). 2025 Apr; 39(6):1099-1106.
-
Clinical Characteristics and Treatment Outcomes in Unilateral Coats Disease: A Global Collaborative Study. Ophthalmol Retina. 2025 Jun; 9(6):570-579.
-
Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections. Ophthalmol Retina. 2025 Apr; 9(4):330-342.
-
Intravitreal Metformin Protects Against Choroidal Neovascularization and Light-Induced Retinal Degeneration. Int J Mol Sci. 2024 Oct 22; 25(21).
-
Bevacizumab for Retinopathy of Prematurity Is Not Associated With Systemic Hypertension. J Pediatr Ophthalmol Strabismus. 2024 Nov-Dec; 61(6):434-441.
-
MicroRNA-based engineered mesenchymal stem cell extracellular vesicles to treat visual deficits after blast-induced trauma. Exp Eye Res. 2024 Oct; 247:110031.